Piper Jaffray analyst Christopher Raymond continues to gather evidence suggesting that Duchenne muscular dystrophy could be the indication for Audentes Therapeutics’ (BOLD) AT720. After finding a second Audentes patent referencing treatment for DMD, and with management stating that they’re ready to leverage their expertise outside of gene replacement therapy, Raymond says in a research note that he “wouldn’t be surprised” if AT720 was targeting “this large neuromuscular disease.” The analyst remains a buyer of Audentes shares into the formal unveiling of AT720 in Q2 of 2019. Raymond has an Overweight rating on the stock with a $45 price target. Sarepta Therapeutics (SRPT) is known as the leader in developing treatments for Duchenne muscular dystrophy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.